簡介

  博士，教授，博士生導師。廣東藥學會、美國化學會（ACS）成員。1994及1997年分别獲武漢大學學士、碩士學位；2000年7月獲中山大學生物有機化學專業博士學位。分别于2001.1-2002.1及2002.8-2003.8年在香港科技大學生物技術研究所進行訪問研究；2003年底入職太阳集团1088vip工作至今。長期堅持藥物化學與藥理學相結合的工作方向，緻力于基于靶标穩定性調控、免疫調控的抗腫瘤、AD等重大疾病的藥物設計；先後主持國家自然科學基金、國家高新技術計劃863項目、教育部重點科技項目、廣東省自然科學基金以及中山大學百人計劃引進人才“行動計劃”基金等多項研究課題。在J. Med. Chem., ACS Chem. Biol., Chem. Commun., Biochem. Pharmacol., Mol. Cancer Thera.等多個專業期刊發表專業論文近百篇；申請國際國内專利20項，其中國内專利獲授權15項，美國專利獲授權2項。

 

研究方向

        藥學多學科融合基礎上的藥物設計與發現：

        1.活性多肽、類天然産物庫的構建；

        2.腫瘤、神經退行性疾病惡性事件中關鍵蛋白的降解與折疊行為調控及藥理意義；

        3.重大疾病相關信号網絡關鍵因子的探針設計與藥物發現

 

科研項目

  1. 基于I型幹擾素調控新機制促進腫瘤“冷-熱”轉換的創新藥物先導物的設計與發現(82373713)，國家自然科學基金，2024.1-2027.12

  2. STING介導的抗腫瘤免疫響應調節先導藥物的設計發現與抗腫瘤作用研究(2022A1515012221)，廣東省基礎與應用基礎研究基金，2022.1-2024.12

  3. 基于ABeta聚集體重組與表面僞裝策略的抗AD藥物設計合成及活性研究(81973174)，國家自然科學基金，2020.1-2023.12

  4. 基于Aβ蛋白N端捕獲的活性環肽設計及其抗AD作用與分子機制研究(21672266)，國家自然科學基金，2017.1-2020.12

  5. 靶向19SRP去泛素化酶的新機制蛋白酶體抑制劑的發現與抗腫瘤研究(81473083)，國家自然科學基金，2015.1-2018.12

  6. 靶向NF-kappaB/p53交叉通路網絡的新型PAC類抗腫瘤活性分子的設計發現與機制研究(81172931)，國家自然科學基金，2012.1-2015.12

  7. 抑制NF-κB激活通路的新型PACs類先導物的發現、作用機制及抗腫瘤研究(30973619)，國家自然科學基金，2010.1-2012.12

  8. 神經退行性疾病信号轉導及新靶标研究(批準号：9351008901000003)，廣東省自然科學基金研究團隊項目，2010.1-2012.12（核心成員）

  9. 多靶标内環境激活式抗耐藥腫瘤先導分子的設計(2008AA02Z304)，國家高新技術863項目，2008.1-2010.12

  10. 基質細胞衍生因子衍生多肽庫的構建及其抗腫瘤轉移作用研究(5001773)，廣東省自然科學基金，2005.1-2007.12

  11. 抑制CXCR4的重組趨化因子衍生肽庫的構建及其生理意義(105133)，國家教育部重點科技項目，2005.1-2007.12

  12. 中山大學百人計劃引進人才“行動計劃”基金，2003年

 

代表性論文

  1. Xiaoquan Wang1, Youqiao Wang1, Anqi Cao, Qinhong Luo, Daoyuan Chen, Weiqi Zhao, Jun Xu, Qinkai Li, Xianzhang Bu* & Junmin Quan*, Development of cyclopeptide inhibitors of cGAS targeting protein-DNA interaction and phase separation. Nature Communications, 2023, 14:6132. https://doi.org/10.1038/s41467-023-41892-5

  2. Xin Yue1, Tingyu Liu1, Xuecen Wang1, Weijian Wu, Gesi Wen, Yang Yi, Jiaxin Wu, Ziyang Wange, Weixiang Zhan, Ruirui Wu, Yuan Meng, Zhirui Cao, Liyuan Le, Wenyan Qiu, Xiaoyue Zhang, Zhenyu Li, Yong Chen, Guohui Wan, Xianzhang Bu*, Zhenwei Peng*, Ran-yi Liu*, Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1/BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy, Acta Pharmaceutica Sinica B, 2023, 13(8):3382e3399.

  3. Li Yunzhi1, Wu Jiaxin1, Jin Chaoying1, Zhang Yiqiu, Wang Jiyu, Wang Xuecen, Li Huixia, Zhang Xiaoyue, Liu Tingyu, Zhou Deyuan, Kuang Yukun, Wu Weijian, Wang Youqiao, Ke Zunfu, Bu Xianzhang*, Yue Xin*, Caged Luciferase Inhibitor-Based Bioluminescence Switching Strategy Enables Efficient Detection of Serum APN Activity and the Identification of Its Roles in Metastasis of Non-Small Cell Lung Cancer, Chem. Eur. J. 2023, e202300655

  4. Weijian Wu1, Huiying Xu1,Chenyang Liao, Youqiao Wang, Ruirui Wu, Jiaxin Wu, Wenlv Zheng, Yunzhi Li, Chaoying Jin, Yuxuan Zhao, Junmin Quan, Xin Yue*, Xianzhang Bu,* Blockade of USP14 potentiates type I interferon signaling and radiation-induced antitumor immunity via preventing IRF3 deubiquitination. Cellular Oncology (2022) 45:1347–1361

  5. Yunzhi Li1, Chaoying Jin1,Huiying Xu, Weijian Wu, Youqiao Wang, Jiaxin Wu, Tingyu Liu, Guohui Wan, Xin Yue,* and Xianzhang Bu*, Identification of 2‑Benzylidene-tetralone Derivatives as Highly Potent and Reversible Firefly Luciferase Inhibitors. ACS Med. Chem. Lett. 2022, 13, 304−311

  6. Haixia Sun, Daoyuan Chen, Sirui Zan, Weijian Wu, Huiying Xu, Chunxiang Luo, Hui Su, Yanqiao Feng, Weiyan Shao, Arabella Wan, Binhua Zhou, Guohui Wan * and Xianzhang Bu* Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand-1 Inhibitor as Immune Modulator for Cancer Therapy, Journal of Medicinal Chemistry 2020, 63, 11286−11301

  7. Yanqiao Feng1,Hui Su1, Yunzhi Li, Chunxiang Luo, Huiying Xu, Youqiao Wang, Haixia Sun, Guohui Wan, Binhua Zhou* and Xianzhang Bu* Degradation of intracellular TGF-b1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events. Chem. Commun., 2020, 56, 2881−2884

  8. Yan, S.; Sun, H.; Bu, X.*; Wan, G.* New strategy for COVID-19: an evolutionary role for RGD motif in SARS-CoV-2 and potential inhibitors for virus infection. Front Pharmacol. 2020, 11, 912.

  9. Liu, Ziyi; Wang, Youqiao; Qin, Wenjing; Chen, Daoyuan; Feng, Yanqiao; Su, Hui; Shao, Weiyan; Zhou, Binhua; Bu, Xianzhang, Raloxifene alleviates amyloid-beta-induced cytotoxicity in HT22 neuronal cells via inhibiting oligomeric and fibrillar species formation. Journal of biochemical and molecular toxicology, 2019, e22395

  10. Daoyuan Chen, Wenjing Qin, Gesi Wen, Bihua Shi, Ziyi Liu, Youqiao Wang, Qiang Zhou, Junmin Quan, Binhua Zhou*, Xianzhang Bu*, Dissociation of haemolytic and oligomerpreventing activities of gramicidin S derivatives targeting the amyloid-β N-terminus, Chem. Commun., 2017, 53, 13340–13343

  11. Gesi Wen1, Daoyuan Chen1, Wenjing Qin, Binhua Zhou, Youqiao Wang, Ziyi Liu, Jun Du, Qiang Zhou, Junmin Quan, Xianzhang Bu*, Stabilizing of Amyloid-β Peptide by the N-terminus Capture is Capable of Preventing and Eliminating Amyloid-β Oligomers. Chem. Commun., 2017, 53, 7673−7676

  12. Xin Yue1, Yinglin Zuo1, Hongpeng Ke, Jiaming Luo, lanlan Lou, Wenjing Qin, Youqiao Wang, Ziyi Liu, Daoyuan Chen, Haixia Sun, Weichao Zheng, Cuige Zhu, Ruimin Wang, Gesi Wen, Jun Du, Binhua Zhou*, Xianzhang Bu*, Identification of 4-arylidende curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Biochem Pharmacol 2017, 137, 29–50.

  13. Gesi Wen, Wenjing Qin, Daoyuan Chen, Youqiao Wang, Xin Yue, Ziyi Liu, Yingnan Cao, Jun Du, Binhua Zhou*, and Xianzhang Bu*, Stabilizing the monomeric amyloid-β peptide by Tyrocidine A prevents and reverses the amyloideogenesis without the accumulation of oligomers Chem. Commun., 2017, 53, 3886–3889.

  14. Baoxia Liang, Ziyi Liu, Yingnan Cao, Cuige Zhu, Yinglin Zuo, Lei Huang, Gesi Wen, Nana Shang, Yu Chen, Xin Yue, Jun Du, Baojian Li, Binhua Zhou*, Xianzhang Bua*, MC37, a new mono-carbonyl curcumin analog, induces G2/M cell cycle arrest and mitochondria-mediated apoptosis in human colorectal cancer cells. European Journal of Pharmacology 2016, 796,139–148.

  15. Jianyong Zhu, Ruimin Wang, Lanlan Lou, Wei Li, Guihua Tang, Xianzhang Bu*, and Sheng Yin*, Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure–Activity Relationships and Discovery of Promising MDR Reversal Agents, J. Med. Chem., 2016, 59(13):6353–6369

  16. Baoxia Liang, Weiyan Shao, Cuige Zhu, Gesi Wen, Xin Yue, Ruimin Wang, Junmin Quan, Jun Du, and Xianzhang Bu*, Mitochondria-Targeted Approach: Remarkably Enhanced Cellular Bioactivities of TPP2a as Selective Inhibitor and Probe toward TrxR, ACS Chem. Biol., 2016, 11 (2), 425–434

  17. Zhang-Hua Sun, Yu Chen, Yan-Qiong Guo, Jie Qiu, Cui-Ge Zhu, Jing Jin, Gui-Hua Tang, Xian-Zhang Bu*, Sheng Yin*, Isolation and cytotoxicity evaluation of taxanes from the barks of Taxus wallichiana var. mairei, Bioorganic & Medicinal Chemistry Letters, 2015, 25, 1240–1243

  18. Cuige Zhu, Yinglin Zuo, Baoxia Liang, Hong Yue, Xin Yue, Gesi Wen, Ruimin Wang, Junmin Quan, Jun Du and Xianzhang Bu* Distinct tubulin dynamics in cancer cells explored using a highly tubulin-specific fluorescent probe，Chem. Commun., 2015,  51, 13400–13403.

  19. Cuige Zhu , Yinglin Zuo , Ruimin Wang , Baoxia Liang , Xin Yue , Gesi Wen , Nana Shang , Lei Huang , Yu Chen , Jun Du , and Xianzhang Bu * Discovery of Potent Cytotoxic Ortho-Aryl Chalcones as New Scaffold Targeting Tubulin and Mitosis with Affinity-Based Fluorescence，J. Med. Chem., 2014, 57 (15), 6364–6382.

  20. L. Huang, Y. Chen, B. Liang, B. XING, G. Wen, S. Wang, X. Yue, C. Zhu, J. Du and X. Bu, Furanyl Acryl Conjugated Coumarin as Efficient Inhibitor and Highly Selective Off-On Fluorescent Probe for Covalent Labelling of Thioredoxin Reductase Chem. Commun., 2014,  50, 6987–6990.

  21. Nana Shanga, Yongxian Shao, Yinghong Cai, Matthew Guan, Manna Huang, Wenjun Cui, Lin He, Yan-Jun Yu, Lei Huang, Zhe Li, Xianzhang Bu*, Hengming Ke*, Hai-Bin Luo*, Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)- one as a phosphodiesterase-5 inhibitor and its complex crystal structure, Biochemical Pharmacology 2014, 89, 86–98 .

  22. H. Liu, Y. Liu, F. Zhang, H. Wang, G. Zhang, B. Zhou, Y. Zuo, S. Cai, X. Bu* and J. Du*, Identification of potential pathways involved in induction of cell cycle arrest and apoptosis by a new 4-arylidene Curcumin analogue T63 in lung cancer cells: a comparative proteomic analysis Mol. BioSyst., 2014, 10, 1320–1331.

  23. Binhua Zhou, Yinglin Zuo, Baojian Li, Hao Wang, Hao Liu, Xianfeng Wang, Xu Qiu, Yun Hu, Shijun Wen, Jun Du, Xianzhang Bu*, Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analogue AC17 Causes NF-κB Inhibition and p53 Reactivation in Human Lung Cancer Cells, Molecular Cancer Therapeutics, 2013, 12(8), 1381–1392.

  24. Yun Hu, Yaqi Yang, Yanjun Yu, Gesi Wen, Nana Shang, Wei Zhuang, Dihan Lu, Binhua Zhou, Xin Yue, Baoxia Liang, Jun Du, Feng Li, Xian-Zhang Bu*, Synthesis and Identification of New Flavonoids Targeting Liver X Receptor β Involved Pathway as Potential Facilitators of Aβ Clearance with Reduced Lipid Accumulation. Journal of Medicinal Chemistry, 2013, 56, 6033–6053.

  25. Binhua Zhou, Jianing Huang, Yinglin Zuo, Baojian Li, Qiang Guo, Baicheng Cui, Weiyan Shao, Jun Du, Xianzhang Bu*, 2a, a novel curcumin analogue, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage, European Journal of Pharmacology, 2013, 707, 130–139.

  26. Hao Liu, BinHua Zhou, Xu Qiu, HongSheng Wang, Fan Zhang, Rui Fang, XianFeng Wang, ShaoHui Cai, Jun Du*, XianZhang Bu*，T63, a new 4-arylidene curcumin analogue,induces cell cycle arrest and apoptosis through activation of the reactive oxygen species–FOXO3a pathway in lung cancer cells，Free Radical Biology and Medicine, 2012, 53, 2204–2217.

  27. Yinglin Zuo, Jianing Huang, Binhua Zhou, Shuni Wang, Weiyan Shao, Cuige Zhu, Li Lin, Gesi Wen, Hongyang Wang, Jun Du, Xianzhang Bu*  Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-kB and Akt signaling, Europe Journal of Medicinal Chemistry, 2012, 55, 346–357.

  28. Yinglin Zuo, Yi Yu, Shuni Wang, Weiyan Shao, Binhua Zhou, Li Lin, Zhuoyu Luo, Ruogu Huang, Jun Du, Xianzhang Bu* Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFa-induced nuclear factor-kB activation inhibition Europe Journal of Medicinal Chemistry, 2012, 50, 393–404.

  29. Yanjun Yu, Yun Hu, Weiyan Shao, Jianing Huang, Yinglin Zuo, Yingpeng Huo, Linkun An, Jun Du, and Xianzhang Bu* Synthesis of Multi-Functionalized Chromeno[2,3-c]pyrrol-9(2H)-ones: Investigation and Application of Baker–Venkataraman Rearrangement Involved Reactions Catalyzed by 4-(Dimethylamino)pyridine, Europe Journal of Organic Chemistry, 2011, 4551–4563.

  30. X Qiu, YH Du, B Lou, YL Zuo, WY Shao, YP Huo, JL Huang, YJ Yu, BH Zhou,J Du， HA Fu* and  XZ Bu*, Synthesis and Identification of New 4-Arylidene Curcumin Analogues as Potential Anticancer Agents Targeting Nuclear Factor-kB Signaling Pathway. J Med Chem, 2010. 53 (23), 8260–8273.

  31. MG Yuan, MX Luo, Y Zhang, X Qiu, J Gui, Y Cao, X. Bu*, YL Ren* and XP Hu, Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies Bioorg & Med Chem  2011,19(3):1189–1196

  32. Z Xiao, LM Lin, ZH Liu, FT Jia, WY Shao, MJ Wang,L Liu, SL Li, F Li* and Bu, X.*, Potential Therapeutic Effects of Curcumin: Relationship to Microtubule- associated Proteins 2 in Abeta1-42 Insult. Brain Res  2010, 1361, 115–123

  33. Y.Huo, X Qiu, WY Shao, JN Huang, YJ Yu, YL Zuo, LK An, J Du and Bu, X.* , New fluorescent trans-dihydrofluoren-3-ones from aldol-Robinson annulation- regioselective addition involved one-pot reaction. Org Biomol Chem 2010. 8, 5048–5052

  34. Shen, Y.D., Tian Y.X, Bu, X. Z.* and L.Q. Gu, Natural tanshinone-like heterocyclic-fused ortho-quinones from regioselective Diels-Alder reaction: Synthesis and cytotoxicity evaluation. Eur J Med Chem 2009, 44, 3915–3921.

  35. Ying Peng Huo, Xu Qiu, Wei Yan Shao, Lin Kun An, Xian Zhang Bu *, Lian Quan Gu; Synthesis of new 2-aryl-6-styryl-2,3- dihydropyridin-4(1H)-one derivatives from curcuminoids. Chinese Chemistry Letters, 2009, 20, 1291–1295

  36. Qiu, X.; Liu, Z.; Shao, W.Y.; Liu,X.; Jing, D.P.; Lu, Y.J.; An, L.K.; Huang, S.L.; Bu, X.Z.*; Huang, Z. S.; Gu, L.Q., Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorgan Med Chem 2008, 16, 8035–8041.

  37. Shao, W.Y.; Cao, Y.N.; Yu, Z.W.; Pan, W.J.; Qiu, X.; Bu, X.Z.*; An, L. K.; Huang, Z. S.; Gu, L.Q.*; Chan, A. S. C. Facile preparation of new unsymmetrical curcumin derivatives by solid-phase synthesis strategy. Tetrahedron Lett 2006, 47, 4085–4089.

  38. Pei, L. X.; Li, Y.M.; Bu, X.Z.*; Gu, L.Q.; Chan, A. S. C. One-pot synthesis of 5,6-dihydroxylated benzo[b]furan derivatives. Tetrahedron Lett 2006, 47, 2615–2618.

  39. Shen, Y.D.; Wu, H.Q.; Zhang, S.L.; Bu, X.Z.*; An, L.K.; Huang, Z.S.; Liu, P.Q.; Gu, L.Q.; Li, Y.M. and Chan, A.S.C. Novel synthesis of o-naphthothiophenequinone derivatives via regioselective Diels-Alder reaction. Tetrahedron 2005, 61, 9097–9101.

  40. Pei, L.X.; Huang, S.L.; Shen, Y.D.; An, L.Q.; Huang, Z.S.; Li, Y.M.; Gu, L.Q.*; Bu, X.Z.* and Chan, A.S.C. Synthesis of novel dihydrofuro[b]-pyridinone derivatives: oxidation coupling of 3-hydroxy-4(1H)-pyridinone with beta-dicarbonyl compounds. Tetrahedron Lett 2005, 46, 5085–5088.

  41. Bu, X.Z.; Wu, X.M.; Ng, N.L.J.; Mak, C.K.; Qin, C.G.; Guo, Z.H. Synthesis of gramicidin S and its analogues via an on-resin macrolactamization assisted by a predisposed conformation of the linear precursors. J Org Chem 2004, 69, 2681–2685.

  42. Bu, X.Z.; Xie, G.Y.; Law, C.W.; Guo, Z.H. An improved deblocking agent for direct Fmoc solid-phase synthesis of peptide thioesters. Tetrahedron Lett 2002, 43, 2419–2422.

  43. Bu, X.Z.; Wu, X.M.; Xie, G.Y.; Guo, Z.H. Synthesis of tyrocidine A and its analogues by spontaneous cyclization in aqueous solution. Org Lett 2002, 4, 2893-2895.

  44. Bu, X.Z.; Huang, Z.S.; Zhang, M.; Ma, L.; Xiao, G.W.; Gu, L.Q. Synthesis of new 1,1-dimethyl-1,2,3,4-tetrahydrophenanthrene derivatives. Tetrahedron Lett 2001, 42, 5737–5740. 

 

主要發明專利

  1. 蔔憲章，王尤橋，張怡秋，一種促進 Aβ 清除的化合物及其制備方法和應用，申請日, 2024-01-15, 中國, 202410054079.X

  2. 蔔憲章，嶽欣，徐慧瑩，伍偉健，一種多芳乙烯β-二酮類化合物或其藥學上可接受的鹽及其應用，授權日, 2023-11-07, 中國, ZL202111250655.0

  3. 蔔憲章，李運之，金超穎，一類2-亞苄基四氫萘酮衍生物及其制備方法和應用，授權日, 2023-06-09, 中國, ZL202210000915.7

  4. 蔔憲章，孫海霞，伍偉健，一種環肽化合物及其應用,授權日, 2022-03-11, 中國, ZL202010840057.8

  5. 蔔憲章，李運之，粟慧，馮豔巧，周斌華，一種可促進 TGF-β1 蛋白靶向降解的化合物及其制備方法與應用, 授權日, 2021-07-06, 中國, CN201911031379.1.

  6. 萬國輝，牛藝，蔔憲章，一種磺胺間甲氧嘧啶衍生物在制備抗腫瘤藥物中的應用, 授權日, 2021-05-25, 中國, CN202010232655.7.

  7. 蔔憲章，陳道遠，溫格思，秦文靜，周斌華，一類環十肽分子及其應用, 授權日,2020-09-04，中國, ZL201710104115.9.

  8. Xianzhang Bu, Cuige Zhu, Xin Yue, Yinglin Zuo, Yu Chen, Gesi Wen, o-phenyl chalcone compounds and uses thereof, 美國, US 9663542 B2；PCT申請日：2015.1.14,美國申請日：2016.11.17，授權日：2017.5.30

  9. Xianzhang Bu, Cuige Zhu, Xin Yue, Yinglin Zuo, Yu Chen, Gesi Wen, o-phenyl chalcone compounds and uses thereof, 美國, US 9988405 B2；PCT申請日：2015.1.14,美國申請日：2016.11.17，授權日：2018.6.5

  10. 蔔憲章，朱翠革，嶽欣，左應林，陳雨，溫格思，鄰苯基查爾酮類化合物及其制備方法和應用，申請号：PCT/CN2015/070651，申請日期：2015.01.14；國際專利PCT申請

  11. 蔔憲章，朱翠革，左應林，杜軍，溫格思，嶽欣，陳雨，一種鄰苯基查爾酮類化合物在熒光探針中的應用，申請号：201410353793.5；申請日期：2014.07.23，授權公告日，2017.05.27

  12. 蔔憲章，朱翠革，嶽欣，左應林，陳雨，溫格思，鄰苯基查爾酮類化合物及其制備方法和應用，申請号：201410032845.9；申請日期：2014.01.23，授權公告日，2016.06.08

  13. 蔔憲章，吳海強，黃磊，陳雨，一種硫氧還蛋白還原酶熒光探針及其制備方法和用途，申請号：201410137070.1；申請日期：2014.04.08，授權公告日：2017.01.04

  14. 蔔憲章，羅海彬，商娜娜，于豔君，杜軍，李哲，蔡穎紅，邵詠賢，何琳，一種取代吡咯色原酮類化合物在制備治療5型磷酸二酯酶相關疾病的藥物中的應用，申請号：201310017288.9；申請日期：2013.01.17, 授權公告日：2015.8.26

  15. 蔔憲章，劉培慶，于豔君，汪煜華，胡雲，邵偉豔，杜軍，羟基取代的黃酮類化合物及其制備方法和應用。中華人民共和國知識産權局。申請号：201110269084.5.申請日期：2011年9月13日

  16. 蔔憲章，胡雲，于豔君，杜軍，邵偉豔，商娜娜，莊玮，陸迪涵，劉巍，陳藝貞，溫格思，氨基取代的黃酮類化合物及其制備方法和應用。中華人民共和國知識産權局。申請号：201110269753.9 申請日期：2011年9月13日, 授權公告日：2014.6.11

  17. 蔔憲章，左應林，杜軍，溫格思，周斌華，商娜娜，芳基取代查爾酮類化合物及其制備方法和應用 中國專利申請号：201110217094.4 授權公告日：2013年12月25日

  18. 蔔憲章，于豔君，邵偉豔，胡雲，黃壯裕，左應林，一種多多取代色原酮并吡咯環類衍生物及其合成方法和應用，中國發明專利，專利号：ZL200910214553.6，申請日：2009.12.31 授權公告日：2012.6.27

  19. 蔔憲章，仇旭，霍應鵬，于豔君，金達平，古練權，具有抗腫瘤作用的多芳乙烯取代beta-二酮類化合物，中國發明專利，申請号：200810220580.X, 申請日：2008.12.30，授權公告号 CN101700995B, 授權公告日：2013.06.05

  20. 蔔憲章，邵偉豔，古練權，曹穎男，于志文，一種合成多肽及其應用,中國發明專利,專利号:ZL 200410077777.4, 授權公告日：2007.2.21